Summary of the EMA March 2022 Draft Qualification Opinion for PROCOVA™

The European Medicines Agency recently released a draft qualification opinion on our PROCOVA™ procedure. The draft opinion provides the regulatory framework for planning and conducting a Phase 2 or 3 TwinRCT™, which leverages historical data and machine learning to reduce sample sizes in clinical trials. This summary provides the following (1) highlights the most important sections of the draft qualification opinion, (2) reviews the critical elements of the PROCOVA™ procedure, and (3) addresses FAQs about the draft opinion and supporting documents. 

To help target trial statisticians understand how to implement PROCOVA™, we’ve created this handbook, PROCOVA™ Handbook for the Target Trial Statistician. This document provides step-by-step guidance for the practical application of PROCOVA™ following a brief overview of the methodology.

Enter your email address to download paper.

Click the link to begin download.
Oops! Something went wrong while submitting the form.

Enter your email address to watch the webinar.

Click the link to watch webinar.
Oops! Something went wrong while submitting the form.

Unlearn Closes $50 Million Series B Funding to Advance the Use of Its Machine Learning-Powered TwinRCTs™ in Clinical Trials


Unlearn Signs Multi-Year Collaboration with Merck KGaA, Darmstadt, Germany to Accelerate Immunology Trials using Twintelligent RCTs™


Success is never a straight line—reflecting on our EMA draft qualification opinion

On March 22, 2022, we reached an historic milestone with the European Medicines Agency’s release of a draft qualification opinion on our 3-step PROCOVA™ procedure.
Collaborators will leverage AI-generated Digital Twins to enable smaller, more efficient pivotal clinical trials.
Led by Insight Partners, financing builds on the company’s momentum in working with leading biopharmaceutical companies to improve clinical trial efficiency.